A detailed history of Gries Financial LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Gries Financial LLC holds 15,978 shares of ABBV stock, worth $2.88 Million. This represents 0.66% of its overall portfolio holdings.

Number of Shares
15,978
Previous 14,788 8.05%
Holding current value
$2.88 Million
Previous $2.54 Million 24.41%
% of portfolio
0.66%
Previous 0.59%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$163.84 - $199.33 $194,969 - $237,202
1,190 Added 8.05%
15,978 $3.16 Million
Q2 2024

Aug 02, 2024

SELL
$154.79 - $180.76 $133,893 - $156,357
-865 Reduced 5.53%
14,788 $2.54 Million
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $92,056 - $104,889
-576 Reduced 3.55%
15,653 $2.85 Million
Q4 2023

Feb 13, 2024

SELL
$137.6 - $154.97 $78,569 - $88,487
-571 Reduced 3.4%
16,229 $2.52 Million
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $667 - $773
5 Added 0.03%
16,800 $2.5 Million
Q1 2023

Jun 21, 2023

SELL
$144.61 - $166.54 $117,857 - $135,730
-815 Reduced 4.63%
16,795 $2.68 Million
Q4 2022

Jan 10, 2023

BUY
$138.31 - $165.87 $119,776 - $143,643
866 Added 5.17%
17,610 $2.85 Million
Q2 2022

Aug 16, 2022

SELL
$137.62 - $174.96 $9,633 - $12,247
-70 Reduced 0.42%
16,744 $2.57 Million
Q1 2022

Apr 29, 2022

SELL
$131.98 - $163.75 $677,321 - $840,365
-5,132 Reduced 23.38%
16,814 $2.73 Million
Q4 2021

Feb 02, 2022

SELL
$107.43 - $135.93 $618,796 - $782,956
-5,760 Reduced 20.79%
21,946 $2.97 Million
Q3 2021

Nov 12, 2021

SELL
$106.4 - $120.78 $534,128 - $606,315
-5,020 Reduced 15.34%
27,706 $2.99 Million
Q2 2021

Aug 09, 2021

SELL
$105.21 - $117.21 $742,256 - $826,916
-7,055 Reduced 17.73%
32,726 $3.77 Million
Q1 2021

May 17, 2021

BUY
$102.3 - $112.62 $4.07 Million - $4.48 Million
39,781 New
39,781 $4.64 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Gries Financial LLC Portfolio

Follow Gries Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gries Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gries Financial LLC with notifications on news.